

24 May 2021

Nuformix plc
("Nuformix" or the "Company")

Directorate Changes

Appointment of Chairman and other Board changes

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the appointment of Dr Alastair Riddell as Non-Executive Chairman of the Board with immediate effect. In addition, the Company announces the resignations of Dr Karl Keegan as Non-Executive Director and Dr Joanne Holland as Chief Scientific Officer.

Dr Alastair Riddell will join Nuformix as Non-Executive Chairman of the Board with immediate effect. Alastair brings a wealth of leadership experience in public and private biotech companies to Nuformix, gained over 30 years in the pharmaceutical, life science and biotech industries, with 20 years as a Board Director. After beginning his career as a medical doctor in hospital and general practice, he moved into clinical development for Lederle (now Pfizer) and Centocor (now J&J) and then sales and marketing for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences, where he led significant fundraises including an IPO on the LSE main list and trade sales to Takeda in Japan and Stem Cells Inc. in the USA. He has also had several roles in UK government initiatives including assessing projects for Innovate UK funding. He then moved to Non-Executive roles including for NASDAQ-listed AzurRx (AZRX), Cristal Therapeutics and was Chairman of AIM quoted Feedback plc and Nemesis Biosciences. Alastair has a BSc from Aston University, a MSc and MBChB from the University of Birmingham and an Honorary Degree of Doctor of Science from Aston University.

Dr Karl Keegan has resigned from the Board, with immediate effect in order to focus on his other executive role that he has recently taken on. Dr Joanne Holland has resigned as a director and an employee of Nuformix from the end of May 2021 in order to pursue other opportunities. However, she will continue as a consultant to Nuformix to advise, in particular, on solid form science and patenting.

Dr Anne Brindley, CEO of Nuformix said: *"I would like to welcome Alastair to the Board of Nuformix and look forward to working with him. Alastair will bring extensive experience of pharma and biotech which will be invaluable as we take Nuformix forward as a Company. I would like to sincerely thank Karl for his valuable and insightful contributions to Nuformix over the last year or so and we wish him all the best for the future.*

"On behalf of the Board, I would also like to thank Jo for her long-standing commitment and contributions to Nuformix. She has been with the Company from its inception providing expert knowledge and input into the design and patenting of novel physical forms of existing drugs that has resulted in the product concepts we have today in the Nuformix portfolio. We are very pleased that Jo will continue to provide support as needed in these areas as the Nuformix portfolio moves forward in development. We sincerely wish Jo all the best in the future and look forward to our continued working together in a renewed capacity."

Dr. Alastair Riddell said: *"I am delighted to be able to join Nuformix as it develops its portfolio of newly formulated established products for new and important therapeutic indications. I look forward to helping the company progress these opportunities to value creation for shareholders in the next few years."*

Enquiries:**Nuformix plc**

Dr Anne Brindley, CEO

+44 (0)1223 627222

Allenby Capital Limited

Nick Athanas / George Payne (Corporate Finance)

Tim Sohal / Matt Butlin (Sales and Corporate Broking)

+44 (0)203 328 5656

Walbrook PR

Anna Dunphy / Paul McManus / Kiki Zaccagnini

+44 (0)207 933 8780

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.